within Pharmacolibrary.Drugs.ATC.N;

model N02CD03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 0.00151,
    adminDuration  = 600,
    adminMass      = 0.225,
    adminCount     = 1,
    Vd             = 0.0039,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fremanezumab is a fully humanized monoclonal antibody targeting calcitonin gene-related peptide (CGRP), used to prevent migraine attacks in adults. It is approved and currently used as a preventive therapy for migraine, reducing headache frequency and severity.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic model reported for adult patients (including healthy subjects and migraine patients) aged 18â€“70 years. Parameters represent results after subcutaneous administration.</p><h4>References</h4><ol><li>L Lionetto, F Cipolla, M Guglielmetti, P Martelletti,Fremanezumab for the prevention of chronic and episodic migraine.,Drugs of today (Barcelona, Spain : 1998),2019<a href='https://pubmed.ncbi.nlm.nih.gov/31050694/'>https://pubmed.ncbi.nlm.nih.gov/31050694/</a></li><li>Luana Lionetto, Martina Curto, Giusy Ylenia Cisale, Matilde Capi, Fabiola Cipolla, Martina Guglielmetti, Paolo Martelletti,Fremanezumab for the preventive treatment of migraine in adults.,Expert review of clinical pharmacology,2019<a href='https://pubmed.ncbi.nlm.nih.gov/31220963/'>https://pubmed.ncbi.nlm.nih.gov/31220963/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N02CD03;
